Novo Nordisk’s oral semaglutide Rybelsus reduced the risk for major adverse cardiovascular events by 14% in people with type 2 diabetes at high cardiovascular risk.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback